* Alfacell Inc., of Bloomfield, N.J., completed a $6 million privateplacement, which, together with cash on hand, should fund thecompany for two years. Alfacell also said it intends to file for listingon NASDAQ.

* Amylin Pharmaceuticals Inc., of Napa, Calif., said it completedenrollment in two Phase III studies of its diabetes drug, pramlitide.The studies, involving about 1,000 patients, are testing pramlitide'sability to reduce blood sugar in patients using insulin.

* Aprogenex Inc., of Houston, raised $2 million through an offeringof convertible notes and warrants. Terms were not disclosed. Thecompany said the money should take it through 1996.

* Genset SA, of Paris, sold an additional 270,000 shares tounderwriters of its recent public offering at $16 each. Net proceeds tothe genomics company now total $99.4 million.

* ImmunoTherapeutics Inc., of Fargo, N.D., said two investmentfunds reached an agreement in principal to purchase five millionshares for $1 million. The Aries Funds also agreed to purchase fourmillion shares from a private investor.

* Somatogen Inc., of Boulder, Colo., began a Phase I trial of itsrecombinant hemoglobin, rHb1.1, as an agent for stimulating redblood cell formation. The study will evaluate safety andhematopoietic activity in about 50 patients with anemia resultingfrom end-stage renal disease.

* The Liposome Co., of Princeton, N.J., received marketing approvalfor Abelcet (amphotericin B lipid complex injection) in Sweden totreat severe, invasive fungal infections in refractory and otherpatients.

* Onyx Pharmaceuticals, of Richmond, Calif., extended andexpanded for three years its May 1995 collaboration with Eli Lillyand Co., of Indianapolis. The companies are trying to understand therole of BRCA1-related pathways in breast cancer and to identifyproteins that interact with BRCA1. Onyx will receive undisclosedresearch support, milestones and royalties.

* PerSeptive Biosystems Inc., of Framingham, Mass., said newexperiments show Peptide Nucleic Acid-based probes can quantifythe length of telomeres, which are the DNA sequences at the end ofchromosomes. Details were published in the May 1996 issue ofHuman Molecular Genetics.

* Sheffield Medical Technologies Inc., of New York, said SequusPharmaceuticals Inc., of Menlo Park, Calif., acquired an option toobtain an exclusive sublicense to Sheffield's liposome-CD4technology as an HIV therapeutic. Sequus paid an up-front fee andhas the option to execute the sublicense. Also, Sequus is funding labwork for the technology.

* Viragen Inc., of Miami, said it signed a letter of intent to form astrategic alliance with The American Red Cross _ BiomedicalServices.

(c) 1997 American Health Consultants. All rights reserved.